#SHIV

Merck’s investigational antiretroviral is a reverse transcriptase translocation inhibitor.

Researchers are looking for ways to reduce the doses needed for on-demand PrEP and the 30-day duration recommended for PEP.

Researchers were also able to make the first-ever estimate of the level of antibodies needed for protection against HIV.

The insert contained the antiretrovirals tenofovir alafenamide, known as TAF, and Vitekta (elvitegravir).

Researchers were also able to make the first-ever estimate of the level of antibodies needed for protection against the virus.

Gene editing in monkeys creates SHIV-resistant immune cells.

Antibodies protect monkeys against SHIV.

Scientists tested the effects of the broadly neutralizing antibody PGT121 and the immune-stimulating agent GS-9620 in monkeys.

Merck’s investigational antiretroviral could one day be dosed only weekly among HIV-negative humans.

Scientists succeeded in editing the animals’ stem cells to resist an HIV-like virus and ultimately shrink their viral reservoir.

This sets the stage for an early human trial of such antibody injections for use as pre-exposure prophylaxis (PrEP) against HIV.

Scientists tested the effects of the broadly neutralizing antibody PGT121 and the immune-stimulating agent GS-9620 in monkeys.

Three antibodies combined into one protected monkeys against a simian version of HIV, opening the door for human trials.

Researchers added more power to the vaccine that showed modest protection against humans in Thailand in 2009.

Recent scientific findings have spawned a renewed commitment to conducting biomedical research on primates.